Mitigating T cell DNA damage during PARP inhibitor treatment enhances antitumor efficacy

Journal:
Science Translational Medicine
Published:
DOI:
10.1126/scitranslmed.adr5861
Affiliations:
7
Authors:
20
Go to article
Institutions Authors Share
Tongji Hospital (TJH), HUST, China
16.500000
16.500000
 0.83
Oregon Health and Science University (OHSU), United States of America (USA)
1.500000
 0.08
Fynn Biotechnologies Ltd., China
1.000000
 0.05
IASO Biotherapeutics, China
1.000000
 0.05
Interested in Oncology and Carcinogenesis?